publication venue for
- Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. 2024
- Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings.. 59:1542-1551. 2024
- Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients.. 58:1247-1253. 2023
- Lack of disease control remains a major barrier to transplant for older patients with AML.. 58:1054-1056. 2023
- Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation.. 58:346-348. 2022
- CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.. 57:1101-1107. 2022
- Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens.. 57:232-242. 2021
- Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.. 57:89-94. 2021
- Physically "fit" for allogeneic stem cell transplant?. 56:2628-2629. 2021
- Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation.. 56:2464-2470. 2021
- Cognitive functioning of older adults prior to hematopoietic stem cell transplantation.. 56:2575-2581. 2021
- Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.. 56:2108-2117. 2021
- Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation.. 56:289-292. 2020
- Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.. 56:137-143. 2020
- Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma.. 55:2331-2334. 2020
- Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.. 55:2204-2206. 2020
- Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation.. 55:780-786. 2019
- Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies.. 55:157-164. 2019
- BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.. 54:1553-1561. 2019
- Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study.. 54:1354-1360. 2019
- End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center.. 54:700-706. 2018
- Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience.. 53:1184-1187. 2018
- Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients.. 53:1418-1427. 2018
- Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.. 50:1379-81. 2015
- Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.. 48:1444-9. 2013